Kura Oncology (KURA) CCO sells 4,345 shares in plan trade

Rhea-AI Filing Summary

Kura Oncology, Inc. (KURA) reported that Chief Commercial Officer Brian T. Powl sold 4,345 shares of common stock on August 21, 2026 at a weighted average price of $11.8903 per share. After this 10b5-1 plan trade, he held 169,269 shares of Kura Oncology common stock directly.

Insider Trade Summary 10b5-1

Net Seller: 4,345 shares

Net Sell 1 txn

Insider Powl Brian T.

Role Chief Commercial Officer

Sold 4,345 shs ($52K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	4,345	$11.8903	$52K

Holdings After Transaction: Common Stock — 169,269 shares (Direct)

Footnotes (2)

1. F1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $11.78 to $12.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold: 4,345 shares Weighted average sale price: $11.8903 per share Sale price range: $11.78 to $12.00 per share +2 more

5 metrics

Shares sold 4,345 shares Common stock sale by Brian T. Powl on August 21, 2026

Weighted average sale price $11.8903 per share Weighted average price for the 4,345 KURA shares sold

Sale price range $11.78 to $12.00 per share Range of individual trade prices within the reported transaction

Shares held after transaction 169,269 shares Direct holdings of Brian T. Powl after the sale

Rule 10b5-1 plan adoption date December 18, 2025 Date Brian T. Powl adopted the trading plan used for this sale

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Form 4

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction ... was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

Form 4 regulatory

"The transaction reported in this Form 4 was effected pursuant"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What insider transaction did KURA report for Brian T. Powl?

Brian T. Powl, Chief Commercial Officer, reported a sale of 4,345 KURA common shares on August 21, 2026 at a weighted average price of $11.8903 per share, leaving him with 169,269 shares held directly.

Was the August 21, 2026 KURA insider sale under a Rule 10b5-1 plan?

Yes. The filing states the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Brian T. Powl on December 18, 2025.

How many KURA shares does Brian T. Powl hold after this transaction?

Following the reported sale, Brian T. Powl directly holds 169,269 shares of Kura Oncology, Inc. common stock.

What price range were the KURA shares sold for on August 21, 2026?

The transaction was executed in multiple trades at prices ranging from $11.78 to $12.00 per share. The Form 4 reports a weighted average sale price of $11.8903 per share.

How many KURA shares were sold in total in this Form 4 transaction?

The Form 4 reports that 4,345 shares of Kura Oncology, Inc. common stock were sold in the transaction on August 21, 2026.

Is this KURA Form 4 transaction classified as a buy or a sell?

The Form 4 classifies the transaction as a sale of common stock (code S), with 4,345 shares disposed of at a weighted average price of $11.8903 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/24/2026 - 05:30 PM Accepted by SEC EDGAR 08/24/2026 - 05:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Powl Brian T.

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2026		S(1)		4,345	D	$11.8903(2)	169,269	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025.

2. This transaction was executed in multiple trades at prices ranging from $11.78 to $12.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

	Teresa Bair, Attorney-in-fact for Brian Powl	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)